
News and Publications
Publication Categories
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
7 Hills Pharma has been awarded a $4.7 million CPRIT grant to advance 7HP935, a first-in-class small molecule gene therapy that enhances hematopoietic stem cell transplantation (HSCT). This therapy aims to improve stem cell engraftment and reduce infection risks, offering a better treatment option for cancer and genetic disorder patients, especially those from ethnic minorities with limited stem cell donor matches.
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.
7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma
7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.
7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19, and Influenza Vaccines
7 Hills Pharma announces the successful completion of a Phase I clinical trial for 7HP349, an oral immunostimulant that enhances immuno-oncology drugs, COVID-19, and influenza vaccines. The study demonstrated excellent safety, tolerability, and pharmacokinetics, paving the way for Phase II clinical trials in solid tumors and vaccination for immunocompromised populations.
7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
7 Hills Pharma announces the first healthy volunteers dosed in its Phase 1 trial of 7HP349, an immunostimulant aimed to enhance immuno-oncology drugs and COVID-19 & influenza vaccines, improving immune responses and increasing effectiveness in older adults.